OPKO Health Inc Q2 2024 Earnings Summary
OPKO Health, Inc. Q2 2024 Earnings Summary
1. Overview
OPKO Health, Inc. reported its financial results for the second quarter of 2024.
2. Key Financial Metrics
Due to the provided information being limited and without explicit total revenue and earnings per share (EPS) values, it's not possible to compare the company’s performance year-over-year (YoY) and quarter-over-quarter (QoQ).
3. Revenue Performance by Segment
Segment | Q2 2024 Revenue | Q2 2023 Revenue | YoY Change |
---|---|---|---|
Diagnostics | $129.8 Million | $127.5 Million | 1.8% |
Pharmaceuticals | $40.6 Million | $43.6 Million | -6.9% |
Interpretation: - Diagnostics : Revenues increased by 1.8% YoY, mainly due to higher clinical test reimbursements. - Pharmaceuticals : Revenues decreased by 6.9% YoY, primarily reflecting reduced international sales and foreign exchange fluctuations.
4. Dividends or Share Repurchase Program
The Board of Directors has authorized the repurchase of up to $100 million of the company's Common Stock.
5. Stock Price Movement
Following the earnings announcement, OPKO Health's stock price experienced a decline of approximately 4.48%.
Note : The summary is based on the provided earnings release content and does not include specific figures for total revenue and EPS from the provided Q2 2024 reports. Therefore, some sections could not be completed due to a lack of detailed information. Please refer to the complete earnings release document for comprehensive financial details.
Genasys Inc Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Toll Brothers Reports Fourth Quarter and Full Year 2024 Financial Results
OilDri Corporation of America Reports Record First Quarter Fiscal 2025 Results
Share